Private equity firm Lilly Asia Ventures and Arch Venture Partners led a $100m Series A round in SciNeuro Pharmaceuticals, a pharmaceutical company. The round saw participation from Boyu Capital, General Atlantic, Sequoia Capital China, TF Capital and Zoo Capital. “The impact of CNS diseases extends beyond patients – to their families and society as well. I am humbled by the shared commitment from our investors. With their support, we are committed to addressing this substantial need by establishing a strong and innovative CNS product portfolio, and providing new and improved treatment options to patients in China and around the world,” Min Li, SciNeuro Founder and CEO.